For research use only. Not for therapeutic Use.
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2].
Carotuximab (TRC105; 300 μg/mL; pretreatment 1 h, and then co-cultured for 12 h) reduces the 7-Ketocholesterol-induced endoglin (Eng) protein levels and pSmad1/5 and pSmad2/3 signaling in human aortic endothelial cells (HAoECs). Carotuximab mediated blockage of Eng prevented 7-Ketocholesterol-induced adhesion and transmigration of monocytes through endothelial monolayers[1].
Carotuximab (TRC105; 2 mg/kg; i.v; every 3 days; for 8 weeks) along with Decitabine results in a more durable anti-leukemic effect in acute myeloid leukemia (AML) xenografts. And also enhances reactive oxygen species (ROS) activity[2].
| Catalog Number | I042144 |
| CAS Number | 1268714-50-6 |
| Purity | ≥95% |
| Reference | [1]. Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918. [2]. June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6(10):e05242. |
